Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00134173 · ClinicalTrials.gov registry record · Phase 3

A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease

A Phase 3 study of Hyperlipidemia and Coronary Disease, sponsored by Pfizer.

Completed
Registry status
Phase 3
Development phase
1,100
Enrollment target
20
Study locations

NCT00134173 is a Phase 3 study of Hyperlipidemia and Coronary Disease that has completed, run by Pfizer. The registered enrollment target is 1,100 participants, above the 376-participant average among 35 other Hyperlipidemia trials with a reported enrollment target (193% higher). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00134173, a Phase 3 study of Hyperlipidemia and Coronary Disease, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 3
Development phase
1,100 participants
Enrollment target
20
Study locations

Study Summary

The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To look at ultrasound images taken in the blood vessels of the heart and to look at various lipids in the blood of people with known coronary heart disease

Conditions Studied

Hyperlipidemia Coronary Disease Coronary Arteriosclerosis

Interventions

  • DRUG atorvastatin
  • DRUG torcetrapib/atorvastatin

Study Locations (20)

California

  • Pfizer Investigational Site - Fresno
  • Pfizer Investigational Site - Los Altos
  • Pfizer Investigational Site - Los Angeles
  • Pfizer Investigational Site - Mountain View
  • Pfizer Investigational Site - Sacramento
  • Pfizer Investigational Site - San Diego
  • Pfizer Investigational Site - San Francisco
  • Pfizer Investigational Site - Santa Rosa
  • Pfizer Investigational Site - Stockton

Connecticut

  • Pfizer Investigational Site - Brandford
  • Pfizer Investigational Site - Farmington
  • Pfizer Investigational Site - Guilford
  • Pfizer Investigational Site - New Haven

Alabama

  • Pfizer Investigational Site - Birmingham
  • Pfizer Investigational Site - Mobile

Colorado

  • Pfizer Investigational Site - Boulder
  • Pfizer Investigational Site - Denver

Florida

  • Pfizer Investigational Site - Atlantis
  • Pfizer Investigational Site - Clearwater

Arkansas

  • Pfizer Investigational Site - Little Rock

Trial Details

FieldValue
Enrollment Target 1,100 participants
Start Date 2003-10
Est. Completion 2006-09
Phase Phase 3

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00134173

The ClinicalTrials.gov registry entry for NCT00134173 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,100 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 376-participant average among 35 other Hyperlipidemia trials with a reported enrollment target (193% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Hyperlipidemia appearing as the primary indexed condition, and to 2 interventions - of which atorvastatin is the first listed.

NCT00134173 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Connecticut, Alabama.

Frequently Asked Questions

What is clinical trial NCT00134173 about?

NCT00134173 is a clinical study titled "A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease". The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To look at ultrasound images taken in the blood vessels of the heart and to look at various lipids in the blood of people with known coronary heart disease

What is the current status of trial NCT00134173?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,100 participants. The study started on 2003-10. Estimated completion is 2006-09.

What conditions does trial NCT00134173 study?

This clinical trial studies the following conditions: Hyperlipidemia, Coronary Disease, Coronary Arteriosclerosis.

What interventions are being tested in trial NCT00134173?

The interventions under investigation include: atorvastatin (DRUG), torcetrapib/atorvastatin (DRUG).

Who is sponsoring clinical trial NCT00134173?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00134173 being conducted?

This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hyperlipidemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hyperlipidemia

All registered trials for this condition

Coronary Disease

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.